HONG KONG, Aug 13, 2020 – (ACN Newswire) – China Medical System Holdings Limited ("CMS", or the "Company", SEHK:867), together with its subsidiaries (the "Group"), a well-established, innovation-driven specialty pharma with a focus on sales and marketing in China, announced its unaudited results for the 6 months ended 30 June 2020 ( the "Reporting Period").
In the first half of 2020, the Group recorded a turnover of RMB3,108.1 million (H1 2019: RMB2,964.4 million), an increase of 4.8% over the same period last year; excluding the effect of the "two-invoice system", turnover was up 4.6% to RMB3,557.1 million (H1 2019: RMB3,401.5 million). Profit for the period recorded an increase of 11.4% to RMB1,300.5 million (H1 2019: RMB1,167.5 million). Declared interim dividend was up 11.8% compared with the same period last year to RMB0.2105 per share (H1 2019: RMB0.1883).
Mr. Lam Kong, Chairman and Chief Executive of CMS, said: "Sustainable product competence is the key competitive factor for future development of enterprises. Adhering to the development strategy with innovative products as the core, the Group constantly expanded the innovative pipeline, while accelerating the registration progress of innovative products in China, so as to fulfill the unmet medical needs in China pharmaceutical market. Meanwhile, the Group continued to optimize the professional promotion system as well as the compliant and refined management system. Empowered by the product competence, promotion capability and efficient management system, the Group achieved steady and good growth."
Product Pipeline
The Group concentrates on the innovative products that are global first-in-class or with the best efficacy or best cost-effectiveness in the same class due to their innovative formulations or drug delivery systems. Capitalizing on its resources of global product development accumulated for more than two decades, as well as the market reputation earned, the Group has established strategic cooperation relationships with a number of leading pharmaceutical companies around the world and made equity investments in innovative R&D companies from the U.K., France, the U.S. and Switzerland. The Group's product pipeline includes 20 innovative products with great market potential and competitive differentiation advantages at relatively high innovation level, covering therapeutic fields including nervous system, ophthalmology, dermatology, endocrine system, oncology, nephrology, immune system, digestive system, anti-infection, etc.
During the Reporting Period, the Group's innovative pipeline continued to expand. The Group successively acquired exclusive licenses of the innovative product Desidustat (a patented new molecular entity for the treatment of anemia in patients with chronic kidney disease) and PLENITY (the U.S. FDA-cleared safe and effective orally-administered weight management product made from naturally derived materials) in Mainland China, HK SAR, Macau SAR, TWN and/or other countries in Asia. Meanwhile, the registration and clinical work of innovative products was accelerated. Two blockbuster innovative products (Diazepam Nasal Spray and Cyclosporine Eye Drops 0.09%) have been granted clinical trial notices issued by China NMPA for comparative PK study and confirmatory clinical trial respectively; the confirmatory clinical trial application of one blockbuster innovative product (Tildrakizumab) has been accepted by China NMPA; and the Phase II clinical trial of one innovative product (CF102) in Israel has yielded positive top line results.
Meanwhile, the Group deployed complex generics and competitive generics and actively worked on their registration in China, so as to capitalize on the opportunities brought by the National Volume-based Procurement to capture additional driving forces for the future development of the Group. As at 30 June 2020, two generics were under the review for marketing approval in China and one was granted clinical trial notice in China.
Existing Product Development
The Group's existing products mainly involve products under cardio-cerebrovascular line (mainly include Plendil, XinHuoSu and Deanxit), digestion line (mainly include Ursofalk, Salofalk, Bioflor and Combizym), ophthalmology line (mainly include Augentropfen Stulln Mono Eye Drops) and dermatology line (mainly include Hirudoid). Through deeply exploring and enhancing the evidence-based medical evidence and reinforcing the expert network construction and academic platform integration, the Group constantly increased products' academic influence and solidified the competitive advantages of the existing products. During the Reporting Period, the Group recorded solid growth across core product lines. The revenue of products under cardio-cerebrovascular line would increase by 4.4% to RMB2,026.6 million if excluding the effect of the "two-invoice system"; the revenue of products under digestion line increased by 12.7% to RMB1,157.9 million; the revenue of products under ophthalmology line decreased by 1.2% to RMB113.8 million; the revenue of products under dermatology line decreased by 0.9% to RMB85.2 million.
Promotion System
During the Reporting Period, the Group focused on the expansion of the promotion network and strengthened the market segmentation as well as the lower-tier market penetration. The Group actively explored the improvement and innovation of the promotion model while solidifying the existing promotion system, so as to accumulate experiences and make deployments in advance for the academic promotion of innovative products. In the meantime, aiming to building a more professional and compliant promotion team with higher execution capability, the Group further perfected the job qualification and employee training system, optimized the remuneration and incentive system, and intensified the compliance training and inspection. In addition, the Group capitalized on digital tools to hold online academic conferences with high frequency. Complying with the industry trend, the Group steadily promoted the construction of the retail network, expanded the coverage of retail chains and terminal stores, and further strengthened the cooperation with e-commerce platforms.
During the Reporting Period, the Group's promotion network covered about 57,000 hospitals and medical institutions in China.
Manufacturing Facilities
As at 30 June 2020, the Group owned pharmaceutical manufacturing sites in Hunan, Hebei and Shenzhen, occupying a total area of more than 110,000 square meters. The Group has the Pharmaceutical Production License and the Pharmaceutical GMP Certificate for various dosage forms such as powder, oral solution, small-volume injections, tablets, hard capsules, etc. With more than two decades of pharmaceutical production experiences, the Group has instituted stringent quality management standards and regulations to guarantee the product quality, ensuring the localized preparation manufacturing of overseas innovative products in China.
Mr. Lam Kong concluded, "The Group focuses firmly on the two core values in the pharmaceutical industry chain: product competence and promotion capability. Capitalizing on our extensive global resources, the Group will continue to expand the innovative pipeline and facilitate the further development and commercialization of drugs in China, so as to enhance product competence. At the same time, the Group will continuously strengthen the professional, compliant and efficient promotion system to achieve sustainable and steady growth. Adhering to the mission of "Offering competitive products and services to meet China's unmet medical needs", CMS will benefit and provide Chinese patients with more effective, safer, and more cost-effective drugs."
Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com
Tag: HealthCare
QBiotics Announces Clinical Collaboration with MSD Targeting Unresectable Melanoma
BRISBANE, AUSTRALIA, Aug 13, 2020 – (ACN Newswire) – QBiotics Group Limited (QGL), a life sciences company developing novel anticancer and wound healing pharmaceuticals, is pleased to announce that it has entered into an agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, NJ, USA), to evaluate use of its lead molecule tigilanol tiglate, in combination with Keytruda(R) (pembrolizumab) in patients with unresectable melanoma.
Dr Victoria Gordon, Managing Director and CEO of QBiotics, said, "We are delighted to announce this collaboration with MSD. Patients with unresectable melanoma who have received prior checkpoint inhibitors currently have limited effective treatment options. Through this program we hope to see that when combined, tigilanol tiglate and Keytruda may produce additive anti-tumour immune responses, and improve outcomes for patients."
The Phase I/II open label 'QBC46-H06' study is a dose escalation and expansion study with the primary objective of determining the maximum tolerated dose or maximum feasible dose of the combination therapy. Secondary measures include assessing tumour responses in both injected tumours and uninjected tumours, as well as clinical efficacy parameters. Patients with unresectable melanoma and who have had exposure to immune checkpoint inhibitors are eligible for the study.
Dr Gordon continued, "This study follows on from encouraging Phase I data where tigilanol tiglate as a monotherapy showed a 27% treatment response rate*, including an 18% complete response with full tumour destruction across a wide variety of solid tumour types(2). Two patients with melanoma that had complete responses also had an abscopal (anenestic) response. Melanoma is the second human application we are pursuing for tigilanol tiglate following on from our Phase I/II clinical trial in patients with Head and Neck Squamous Cell Carcinoma (HNSCC) which commenced in December 2019".
Tigilanol tiglate is a small molecule administered by intratumoural injection directly into the solid tumour mass. Once injected, it has a multi-modal action including (i) rapid, but highly localised, inflammatory responses, (ii) increased permeability and destruction of tumour vascular endothelium, and (iii) rapid tumour cell death by oncosis(1).
*27% treatment response rate (n=6); 18% complete response rate (n=4)2.
Issued by QBiotics Group Limited – www.qbiotics.com
For further information
Dr Victoria Gordon, CEO & Managing Director, QBiotics Group
victoria.gordon@qbiotics.com or + 61 418 453 737
For media enquiries
Jane Lowe, IR Department
jane.lowe@irdepartment.com.au or +61 411 117 774
About QBiotics
QBiotics is a public unlisted Australian life sciences company which discovers, develops and commercialises novel anticancer and wound healing products for human and veterinary markets. Its lead product, tigilanol tiglate, is an anticancer pharmaceutical targeting a range of solid tumours across multiple species. QBiotics' business model is to develop products that have application in both veterinary and human markets. Success in the veterinary programs validates QBiotics technology and de-risks human development, while generating early, non-diluting revenues. https://qbiotics.com
About Tigilanol tiglate
Tigilanol tiglate is a small molecule that is being tested as an intratumoural treatment for solid tumours. Its effect on tumours is multimodal and involves injected tumour responses as well as distal responses in non-injected tumours. Complete destruction of the injected tumour is mediated via tumour vascular disruption as well as death of tumour cells by oncosis1. Following tumour destruction, rapid wound healing has been shown to ensue.
A single injection of tigilanol tiglate has been shown in canine patients to ablate (completely destroy) 75% of treated tumours(3). Veterinary use of tigilanol tiglate (branded STELFONTA(R)) has received marketing authorisation by the European Medicines Authority and the Veterinary Medicines Directorate in the United Kingdom as a treatment for canine mast cell tumours. STELFONTA(R) is also under review by the US Food and Drug Administration – Center for Veterinary Medicine and the Australian Pesticides and Veterinary Medicines Authority. STELFONTA(R) is partnered with Virbac, a global animal health company and launched in Europe in April 2020.
References
1. Boyle et al., (2014) Intra-tumoural injection of the novel PKC activator EBC-46 rapidly ablates tumours in mouse models. PLoS One 9:e1068887. DOI: 10.1371/journal.pone.0108887.
2. Panizza et al., (2019) Phase I dose-escalation study to determine the safety, tolerability, preliminary efficacy and pharmacokinetics of an intra tumoural injection of tigilanol tiglate (EBC-46). EBioMedicine 50: 433-441.
3. De Ridder et al., (2020). Randomized controlled clinical study evaluating the efficacy and safety of intratumoral treatment of canine mast cell tumors with tigilanol tiglate (EBC-46). Journal of Veterinary Internal Medicine. 1-15. DOI: 10.1111/jvim.15806
Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com
Azelis releases first sustainability report as a testimony of global sustainability efforts
SINGAPORE, Aug 11, 2020 – (ACN Newswire) – Azelis, a leading distributor of specialty chemicals and food ingredients, is proud to release its first sustainability report as a testimony of its global sustainability efforts and actions. With this sustainability report, Azelis covers its 2019 group-wide sustainability performance and demonstrates how its commitments to sustainability are put into action, by creating shared value with our innovative and sustainable products and having a positive impact on the communities around the globe.
 |
Highlights & rationale
– After its second and consecutive EcoVadis Gold rating and membership to Together for Sustainability as announced earlier this year, Azelis now releases its first sustainability report.
– The company is convinced that only innovation and sustainable business can provide long-term partnerships with customers and suppliers, as well as considerable benefits to society.
– Azelis' strong focus on sustainability is in line with Azelis' strategy to become the global benchmark for sustainability in the chemicals and food ingredients distribution industry.
Being a global service provider focused on the development of innovative formulations, sustainability has always been part of Azelis' identity. Soon after initial commitments to Responsible Care(R) & Responsible Distribution(R), Azelis laid the groundwork for its Corporate Social Responsibility (CSR) Program in 2015, following the Paris Agreement on climate change and the 2030 Agenda for Sustainable Development by the United Nations. Azelis' CSR program is based on the United Nations Global Compact initiative, ISO 26000 and the Global Reporting Initiative (GRI), and is built on 25 KPIs within four main pillars: People, Sustainable procurement, Fair business practices and Resources & environment.
Dr. Hans Joachim Muller, Azelis Chief Executive Officer, comments: "Year 2020 marks a few important sustainability milestones for Azelis. After our second EcoVadis Gold rating and our membership to Together for Sustainability earlier this year, we are now excited to release our first sustainability report in which we bring Azelis' global sustainability efforts to life. We hope that this report will influence and excite our partners about the ever-important sustainability journey, whilst also inspiring and exciting them about our transition to a sustainable business. We are confident that only a joint effort for more sustainable solutions will strengthen the relationships with our business partners who are equally responsible and equally dedicated, and will result in preservation of resources for future generations."
Maria J. Almenar Martin, Group Safety, Health, Environment and Quality (SHEQ) and Sustainability Director, adds: "It's our genuine belief that only innovation and sustainable business models can offer long-term partnerships with customers and suppliers, as well as considerable benefits to society. We're continually investing in the development of a new generation of sustainable formulations through the work done in our network of laboratories, whilst also introducing new initiatives to develop strategies that mitigate business risks as a consequence of climate change and social unrest. We hope this sustainability report gives our partners a clear view of our ambitions and goals, and our colleagues another confirmation of how sustainability is deeply-rooted in all we do."
Sustainability is a key pillar of Azelis' strategy, next to digitalization and our aspiration to be the leading innovation service provider for the industries we serve. Azelis is actively working towards the transition to a sustainable future by being a progressive employer that fosters equal opportunities and embraces diversity across its business; by creating innovative sustainable formulations in its labs; by ensuring the sustainable use of resources whilst continually reducing the environmental impact of its business; and by conducting its business in a responsible way.
Contact information
Azelis
Marina Kaptein
Group Communications Director
T: +32 3 613 0125
E: marina.kaptein@azelis.com
About Azelis
Azelis is a leading distributor of specialty chemicals and food ingredients present in over 50 countries across the globe with around 2,200 employees. Our knowledgeable teams of industry, market and technical experts are each dedicated to a specific market within Life Sciences and Industrial Chemicals. We offer a lateral value chain of complementary products to about 45,000 customers, creating a turnover of EUR 2.15 billion (2019).
Throughout our extensive network of more than 60 application laboratories, our award-winning technical staff help customers develop formulations. We combine a global reach with a local focus to offer a reliable, integrated service to local customers and attractive business opportunities to principals. And we believe in building and nurturing solid, honest and transparent relationships with our people and partners.
Impact through ideas. Innovation through formulation.
www.azelis.com
Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com
Epazz Engages PCAOB Auditor in Order to Uplist to the OTCQB; Releases Contact Tracing Update to DeskFlex for Covid-19 Back to School
CHICAGO, IL, Aug 11, 2020 – (ACN Newswire) – via NEWMEDIAWIRE — Epazz Inc. DeskFlex (OTC: EPAZ), a cloud-computing software provider company, announced today that it has engaged a PCAOB Auditor to audit 2018 and 2019 financials. Once the audit is complete, the company will uplist to OTCQB to provide more substantial transparency to investors.
DeskFlex desk and room scheduling system releases its newest software feature, the Contact Tracing tool to prevent and contain a possible outbreak in the workplace, schools, and campuses. DeskFlex's Contact Tracing software screens students, faculty, employees, and registered users for symptoms of COVID infection upon logging into the system. It sends notifications to administrators when employees and students breach the social distancing protocols, and it allows contactless check-in and checkout reservations. Using the Contact Tracing tool, administrators can monitor contamination in their campuses and can act decisively to swiftly locate, notify, and isolate possibly infected individuals.
DeskFlex's desk booking system has been in the software business since 1997, providing exceptional desk hoteling and intelligent conference room booking software that is useful in many industries, including Education, Health, Finance, Business, Government, and Enterprise. Epazz acquired DeskFlex in 2008 and has been making significant updates to the office hoteling system. Since the start of the COVID-19 pandemic, DeskFlex's room booking system has been continuously upgrading its office reservation software to tighten health safety and security in the offices, schools and financial districts.
DeskFlex's desk hoteling software integrates COVID compliant software and hardware devices such as the Social Distancing, Automatic Desk Sanitation, Visitor Management, Bluetooth beacons, Thermal Scanner, Mask Detection and Contactless Room Displays. The software upgrades aim to provide organizations the essential tools and technology to make offices, classrooms, and campuses safe for students, faculty, and employees.
According to Shaun Passley, Ph.D., CEO of Epazz, Inc., "We are pleased to announce that DeskFlex's desk & room booking software is now more adept in preventing COVID-19 infections from happening in the offices and schools by automation of desk sanitation, integrated contact tracing ability, monitoring visitor, social distancing features, mask detection, and thermal scanners. Our team works hard to continuously improve our room scheduling system in order to better prevent and contain infection in the offices and schools."
About DeskFlex.com
DeskFlex is a desk booking solution and room reservation software for conference rooms, workspaces, desks, car parking spaces, equipment, hoteling, and HotDesking, which helps office managers accommodate the occasional needs of mobile workers while reducing rent and facility costs. DeskFlex lets employees reserve space in advance or claim desks right away. It adjusts the telephone switch (PBX), so calls ring at the "desk du jour." DeskFlex includes check-in, point-and-click floor maps, a web browser, a local kiosk, Outlook integration, and conference room scheduling.
About Epazz, Inc. (www.epazz.com)
Epazz, Inc., is a leading cloud-based software company that specializes in providing customized cloud applications to the corporate world, higher-education institutions, and the public sector. Epazz BoxesOS(TM) v3.0 is a complete web-based software package for small- to mid-size businesses, Fortune 500 enterprises, government agencies, and higher education institutions. BoxesOS provides many of the web-based applications organizations would otherwise need to purchase separately. Epazz's other products are K9Sky.com kennel software and the Provitrac applicant tracking system.
SAFE HARBOR
This is the "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: certain statements contained in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by the use of forward-looking words such as "may," "expect," "intend," "estimate," "anticipate," "believe," and "continue" (or the negation thereof) or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from future results or those implied by such forward-looking statements. Investors are cautioned that no forward-looking statement is a guarantee of future performance and that actual results may differ materially from those contemplated by such forward-looking statements. Epazz, Inc. assumes no obligation and has no intention of updating these forward-looking statements. It has no obligation to update or correct information prepared by third parties that are not paid for by Epazz, Inc. Investors are encouraged to review Epazz, Inc.'s public filings on SEC.gov and otcmarkets.com, including its unaudited and audited financial statements and its OTC market filings, which contain general business information about the company's operations, results of operations, and risks associated with the company and its operations.
CONTACT: For more information, please contact
Investor Relations
investors@epazz.net
(312) 955-8161
www.epazz.com
Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com
Milestone for Biowin’s Rapid COVID-19 Nucleic Acid Detector
BEIJING, Aug 6, 2020 – (ACN Newswire) – Changzhou Biowin Pharmaceutical Co., Ltd. ("Biowin"), a Chinese biotech company focusing on diagnostic product R&D and high-tech biomedical manufacturing, has announced that their rapid COVID-19 nucleic acid detection kit has passed the laboratory evaluation tests. Designed for individual use at home or in the office, the RT-LAMP nucleic acid and easy-sample test kit is fast, portable and affordable.
 |
 |
 |
Early detection is of primary importance to the prevention and control of COVID-19. Rapid detection reflects in the efficacy of follow-on events including treatments following diagnosis and isolation or quarantine to prevent further transmission. At the 'Two Sessions' in May, Premier Keqiang Li spoke about detection in the battle against coronavirus, and encouraged the industry to develop a nucleic acid technology that was fast, accurate and convenient, with no lab, as soon as possible.
As expected, Biowin's "Novel Coronavirus (COVID-19) Nucleic Acid Test Kit (RT-LAMP)" can be carried anywhere and used at any time, allowing individuals privacy and an accurate, real-time understanding of their status, so they can return to work, business and markets with ease. For completion of the full development process, Biowin is in discussions with its partners in relevant countries and regions regarding clinical trials.
Biowin entered an LOI on July 27 with Beijing-based Shineco, Inc (Nasdaq: TYHT), a producer and distributor of Chinese herbal medicines, and organic agricultural and hemp products in China. Shineco is to acquire a 73.7% interest, and join Biowin as it steps into the market for COVID-19 nucleic acid detection. On August 4, the BoD appointed Dr. Fengming Liu, CEO and Chief Scientist of Shienco, Inc, to guide the company through this strategic transformation,
INTERVIEW with Dr. Fengming Liu, CEO and Chief Scientist, Shienco, Inc.
– Q: Biowin Pharmaceutical Co., Ltd. is known for quality biotechnology development and industrial operation team. Can you mention your personal experience, as a nationally distinguished expert and leading returnee?
– Dr. Liu: I obtained my doctoral degree in cardiovascular medicine from Peking Union Medical College, and later received my post-doctoral training at Dartmouth College in the USA. In business, I successfully operated a number of bioengineering technology enterprises before becoming the General Manager of Biowin. I presided over 5 national projects and 8 local projects, contributing in the fields of biopharmaceutical, clinical diagnostic reagents and functional food development. I have organized more than 60 patent applications, and have obtained 48 market approvals for new drug and in vitro diagnostics from the Chinese FDA.
– Q: It has been nearly half a year since the worldwide outbreak of COVID-19, and it has not been effectively controlled yet. What are the main reasons for this situation now?
– Dr. Liu: The main reason is that some countries or regions are currently facing a variety of problems, which can not be effectively solved. I think there exists 4 main problems. First, insufficient detection capacity: virus nucleic acid detection is the main method currently used, but it needs to be operated by specialized instruments and professionals, so the current detection capacity is short of actual requirements; Second, the legal system is not ready to deal with epidemic disease like Covid-19: effective isolation and control for mild and asymptomatic infected people is an important measure to reduce or prevent the spread of the disease. However, many western countries can not implement the unified isolation control for the undiagnosed and latent infection population due to the lack of legal support.
Therefore, timely detection of mild and asymptomatic infections and isolation and control according to the law is an effective means of epidemic prevention and control; Third, insufficient public cooperation: for mild and asymptomatic infected people, especially in other countries, there are such phenomena as unwilling to inspect, unwilling to report, deliberately concealing and not cooperating with the follow-up prevention and treatment management, which leads to the continuous increase of infectious sources; Fourth, the contradiction between returning to work and epidemic prevention and control: a large number of undiagnosed mild and asymptomatic infected people largely exist in the group who have returned to work, which will lead to further spread of the disease, and make it harder to be controlled.
– Q: The world is facing insufficient detection capacity, can you give us a detailed introduction of this home nucleic acid detector in a language that is easy for the public to understand?
– Dr. Liu: Our detector is based on the nucleic acid test kit (RT-LAMP) and developed by using genetic engineering and immune detection technology. It is mainly used for the detection of various viral nucleic acids, especially for the current nucleic acid detection of coronavirus, which can be used at home. It has the advantages of small size, convenient use, low price, high detection sensitivity, low risk of cross infection and broad detection coverage. It can also be used as a screening tool for large sample centralized detection. We just finished the laboratory research test and require further clinical trials to be fully approved..
– Q: What are the characteristics of this domestic nucleic acid detector compared with other existing nucleic acid detection technologies?
– Dr. Liu: Nucleic acid detection is the only way to recognize the coronal virus. The existing fluorescent PCR detection reagents must be operated by professionals in specific molecular laboratories and corresponding large-scale instruments, which greatly limits the detection progress and cannot cover all the population in the control area in a short time. By using at-home nucleic acid detector produced by our company and accompanied by our sampling technology and our nucleic acid detection reagent, ordinary people can complete sampling and testing independently at home without the help of professional testing personnel. Compared with other existing nucleic acid detection technologies on the market, it is more convenient, faster with higher sensitivity and accuracy, and low average detection cost. It can thoroughly help our society solve problems like difficulty in appointment, expensive detection and cross infection risk, etc., and is suitable for effective monitoring of coronal virus in companies or communities.
– Q: The current situation of the epidemic situation is still not optimistic, especially in foreign countries. A large number of ordinary people are still dominated by the fear brought about by coronavirus. So we need a quick and effective easy-taken nucleic acid detector. When can your nucleic acid detector be put on the market to meet the huge demand?
– Dr. Liu: The home nucleic acid detector is progressing well in clinical trials, and will soon contribute to international efforts at prevention and control of COVID-19 . In terms of reagents, Biowin has developed 3 nucleic acid testing products: a novel coronavirus (COVID-19) IgG/IgM antibody test kit (colloidal gold) has already received the CE certification, while the novel coronavirus (COVID-19) nucleic acid test kit (fluorescence RT-PCR), and novel coronavirus (COVID-19) nucleic acid test kit (RT-LAMP) are applying for the process. With respect to testing instruments, we are applying for the registration certificate of medical devices and preparing for trial production. At present, the self collecting disposable nucleic acid detection sampler has obtained the approval certificate of medical device registration, and is in production.
Biowin's home nucleic acid detector is composed of two main parts: self sampling technology and nucleic acid testing instrument. It requires no laboratory environment and does not rely on medical staff. With it, people can easily complete the detection at home and get results within 30 minutes. It is expected that everyone can achieve scientific and accurate prevention and control of COVID-19 in the process of returning to work and production. We hope that this product will enter the market quickly, and that the world will win in its fight against COVID-19 through technological innovation.
About Changzhou Biowin Pharmaceutical Co., Ltd
Established in Changzhou, China in 2012, Changzhou Biowin Pharmaceutical Co, Ltd focuses on R&D, manufacture and distribution of point-of-care diagnostic test kits (POCT). The Company currently has 33 in vitro diagnostics products with marketing approval, 12 Chinese patents, and 28 Chinese patent applications, covering a variety of diseases including heart disease, infectious diseases, stroke, kidney function, diabetes, cancer and bone metabolism disorders. Biowin has a well-established diagnostics R&D laboratory and five technology platforms, and a rapid response system for the delivery of emergency-use in vitro diagnostics products. For more information, please visit http://www.czbiowin.com/.
About Shineco, Inc.
Incorporated in Delaware in August 1997 and headquartered in Beijing, Shineco is a holding company. Through its subsidiaries and related entities, Shineco undertakes vertically- and horizontally-integrated production, distribution, and sales channels to provide health and well-being focused plant-based products in China. Utilizing modern engineering technologies and biotechnologies, Shineco produces, among other products, Chinese herbal medicines, organic agricultural produce, and specialized textiles. For more information, please visit http://tianyiluobuma.com.
Media contact:
Changzhou Biowin Biopharm Co., Ltd
Contact Person: Yue Liu
Telephone: +86 18850050087
Website: http://www.czbiowin.com
Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com
Made-in-Singapore Cancer Drug ETC-159 Advances Further in Clinical Trials
SINGAPORE, Jul 30, 2020 – (ACN Newswire) – Made-in-Singapore cancer drug, ETC-159, has achieved a new developmental milestone in achieving "First Patient First Visit[1]" in Phase 1B. The first dose of ETC-159 has been administered to patients in this new phase of clinical testing, which for the first time, will look at efficacy in addition to assessing the safety of ETC-159 in treating different types of cancers.
 |
 |
 |
From L-R: Ms Sylvia Gan, Senior Research Manager; Ms Nurul Rozaini, Research Associate (Photo credit: A*STAR) |
This clinical study will include subgroups of colorectal, endometrial and ovarian cancer patients from two sites in Singapore (National University Cancer Institute, Singapore and National Cancer Centre Singapore) and up to seven clinical sites in the United States, including four confirmed sites, The University of Texas MD Anderson Cancer Center (Houston, Texas); University of Colorado (Aurora, Colorado); Washington University in St. Louis (Missouri); and Duke University (Durham, North Carolina). The trial is expected to be completed by 2023 at the latest.
ETC-159 was jointly developed by Duke-NUS Medical School (Duke-NUS) and the Agency for Science, Technology and Research (A*STAR), and first entered clinical trials in June 2015[2]. ETC-159 targets a range of cancers including colorectal, endometrial, ovarian and pancreatic cancers, which contribute to a significant fraction of Singapore's cancer burden. A subset of these cancers are caused by hyperactivity in a cell signalling pathway known as the Wnt pathway.
ETC-159 is an upstream inhibitor of the Wnt pathway and the clinical trial will determine to what extent this drug can slow or halt the growth of Wnt-high cancers or if ETC-159 can enhance the activity of immunotherapy in those patients that normally do not respond to immunotherapy. It has previously been shown that increased expression of Wnt pathway related genes is associated with drug resistance and exclusion of tumour-killing immune cells in the targeted types of cancers. The clinical trial uses ETC-159 to block the Wnt pathway so that immune cells can infiltrate the tumour. The trial will also combine ETC-159 with the immune checkpoint inhibitor pembrolizumab to stimulate the immune cells to kill tumour cells.
The Experimental Drug Development Centre (EDDC), a national platform for drug discovery and development, brought ETC-159 to the successful completion of Phase 1A clinical trials in July 2018. In that phase, proof of the drug's mechanism of action was achieved and a safe dose level established in 32 patients with advanced solid tumours.
EDDC, together with POLARIS[3] at A*STAR's Genome Institute of Singapore (GIS), and the Diagnostics Development (DxD) Hub, have also developed a novel diagnostic test in agreement with the US FDA, to identify a particular subgroup of colorectal cancer patients predicted to respond well to ETC-159 due to the presence of gene fusions involving R-spondin genes (RSPO2 or RSPO3) in their tumours. Such patients comprise only about 8% of colorectal cancers and will be identified upfront, based on left-over tumour tissue to be included in Phase 1B of the study. The test will be performed at POLARIS for all clinical samples from this trial.
"A significant milestone for EDDC and Singapore has been achieved with the progression of ETC-159 into Phase 1B clinical trials. We are grateful for the collaboration and input of our partners, such as Duke-NUS, POLARIS, clinical investigators and others within Singapore and beyond, which has enabled the successful completion of the Phase 1A trial and led us to initiate this next critical stage of ETC-159 development. We are optimistic about rapidly recruiting patients for the next phase of the clinical trial given the unmet need and opportunity ETC-159 brings to these patients, and will continue leveraging great science to make great medicines." – Professor Damian O'Connell, CEO EDDC, A*STAR
"The progression of ETC-159 to this exciting new phase of study is the result of a tremendous Singapore team effort, spanning from basic bench science to international clinical trials. With this critical study, we will learn whether ETC-159, by targeting a set of cancers that has previously been untreatable, will indeed help patients in Singapore and internationally. This important milestone is yet another testament to the research excellence and strong collaborations Singapore can achieve with focused effort. I hope this is just one of many such achievements." – Professor David Virshup, Duke-NUS Medical School
"This study will help address a critical and unmet need in gastrointestinal cancers. The novel design to molecularly screening for R-spondin fusion colorectal cancers that may be driven by the Wnt pathway and to target them with ETC-159 and immunotherapy has never been done before. Furthermore, most gastrointestinal cancers particularly colorectal cancers do not respond to immunotherapy. This may be due to suppression of immune cells in the tumour by Wnt-related pathways. We hope that by combining ETC-159 and immunotherapy we can circumvent this problem and achieve long-lasting responses for our patients." – Dr Matthew Ng, Senior Consultant, National Cancer Centre Singapore (NCCS)
"The incidence of ovarian and endometrial cancers is rising in the developed world, with many patients presenting at advanced stages of the disease. Despite initial responses to chemotherapy, the majority of patients with advanced ovarian and endometrial cancer will experience disease recurrence and eventually develop treatment refractory disease. At the National University Cancer Institute, Singapore (NCIS), we have long recognised this unmet medical need and have consistently been working with various academic and industry partners to develop new therapeutic approaches for these hard to treat gynaecological cancers. This clinical trial represents a novel and exciting therapeutic concept for the treatment of ovarian and endometrial cancers. In our continual drive to find better treatments for our patients, we certainly look forward to adding this study to the burgeoning portfolio of early phase trials at the NCIS Developmental Therapeutics Unit." – Associate Professor David Tan, Senior Consultant, National University Cancer Institute, Singapore (NCIS)
For more information on the ETC-159 clinical trials, please visit:
https://clinicaltrials.gov/ct2/show/NCT02521844
Relevant images can be downloaded from:
https://tinyurl.com/y3kodlbk
For media queries and clarifications, please contact:
Mr Robin Chan
Head, Corporate Communications
Agency for Science, Technology and Research (A*STAR)
Tel: +65 6826 6281
HP: +65 9830 2610
Email: robin_chan@hq.a-star.edu.sg
Lekshmy Sreekumar, Ph.D.
Communications
Duke-NUS Medical School
Tel: +65 6516 1138
Email: lekshmy_sreekumar@duke-nus.edu.sg
About the Experimental Drug Development Centre (EDDC)
The Experimental Drug Development Centre (EDDC) is a national platform for drug discovery and development formed in 2019 from the integration of A*STAR drug discovery and development units, namely, the Experimental Therapeutics Centre (ETC), Drug Discovery and Development (D3), and Experimental Biotherapeutics Centre (EBC). Together, these three units have forged partnerships with more than 70 academic institutions and 25 companies, locally and internationally, with close to 20 licensing deals executed.
The Centre will continue to champion public-private partnerships in the drug development industry. EDDC will allow for better coordination and optimised use of public sector resources, giving industry partners and Singapore greater ability to translate discoveries into new medicines for patients.
EDDC possesses a full range of drug discovery capabilities, including assay development, high throughput screening, antibody cloning, medicinal chemistry and ADME/toxicology. These capabilities allow EDDC to identify drug hits and leads, and develop them to the preclinical candidate stage in-house. In addition, EDDC enables translational drug development activities by having the internal expertise to support candidates through First-in-Human/Patient Phase 1 studies as well as being able to conduct Proof-of-Mechanism or Proof-of-Concept Studies.
About the Agency for Science, Technology and Research (A*STAR)
The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector R&D agency, spearheading economic-oriented research to advance scientific discovery and develop innovative technology. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit society.
As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by contributing to societal benefits such as improving outcomes in healthcare, urban living, and sustainability.
We play a key role in nurturing and developing a diversity of talent and leaders in our Agency and research entities, the wider research community and industry. A*STAR's R&D activities span biomedical sciences and physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit www.a-star.edu.sg.
Follow us on
– Facebook https://www.facebook.com/HQastar/
– LinkedIn https://www.linkedin.com/company/a-star
– Instagram https://www.instagram.com/astarsingapore/
– YouTube https://www.youtube.com/astartv
About Duke-NUS Medical School
Duke-NUS is Singapore's flagship graduate entry medical school, established in 2005 with a strategic, government-led partnership between two world-class institutions: Duke University School of Medicine and the National University of Singapore (NUS). Through an innovative curriculum, students at Duke-NUS are nurtured to become multi-faceted 'Clinicians Plus' poised to steer the healthcare and biomedical ecosystem in Singapore and beyond. A leader in ground-breaking research and translational innovation, Duke-NUS has gained international renown through its five signature research programmes and nine centres. The enduring impact of its discoveries is amplified by its successful Academic Medicine partnership with Singapore Health Services (SingHealth), Singapore's largest healthcare group. This strategic alliance has spawned 15 Academic Clinical Programmes, which harness multi-disciplinary research and education to transform medicine and improve lives. For more information, please visit www.duke-nus.edu.sg.
[1] "First Patient First Visit" is a term used in the pharmaceutical industry to refer to the administration of the first dose of a compound or drug product to the first patient at his or her first visit in a clinical trial.
[2] "First made-in-Singapore cancer drug enters clinical testing:" A*STAR press release, July 16, 2015. National Archives of Singapore.
[3] POLARIS (Personalized OMIC Lattice for Advanced Research and Improving Stratification) https://www.a-star.edu.sg/polaris/
Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com
Theragen Bio analyzes Korea’s largest COVID-19 patient and coronavirus genomic data
SEOUL, KOREA, Jul 28, 2020 – (ACN Newswire) – Theragen Bio is conducting joint research on developing a new coronavirus (COVID-19) genomic big data in collaboration with the Korea Research Institute of Chemical Technology (KRICT), Kyungpook National University Hospital, and the Daegu Metropolitan Government.
 |
The study will analyze the full genome of each patient and the SARS-CoV-2 virus using samples from approximately 1,000 COVID-19 patients in Daegu and Gyeongsangbuk-do provence, the largest coronavirus genomic analysis to be conducted in Korea.
Through this study, Theragen hopes to identify the infection correlation between patient genome and the SARS-CoV-2 virus genome, and apply it to future vaccine development. Theragen identified the genetic correlation while establishing big data for SARS-CoV-2 mutations.
Based on its own Next Generation Sequencing (NGS), Theragen's ultra-sensitive Covid-19 RNA analysis system can decode over 30,000 full-legnth RNA sequences per virus. The SARS-CoV-2 virus mutates frequently, however the system can check RNA mutation, replication, and generation.
In addition, the evolution of the SARS-CoV-2 virus can be traced back to understand the transmission mechanisms between humans and predict clinical patterns, identify high-risk groups, improve the efficiency of PCR-based diagnosis, and secure evidence for prevention and prevention strategies.
Hwang Tae-soon, the CEO of Theragen Bio, explains, "This research is the first attempt to analyze whether there are differences in infection susceptibility depending on the genetic predisposition of infected patients as well as mutations and the evolution of the virus. It will be applicable to various infectious diseases in the future, as well as clinical prediction and vaccine development."
In April, Theragen Bio collaborated on research for a high-resolution genetic map of SARS-CoV-2, developed by Narry Kim, head of the RNA research group at the Institute for Basic Science (IBS), Hyeshik Chang, a professor at the Department of Biological Sciences, Seoul National University, in collaboration with Korea National Institute of Health (KNIH) within Korea Centers for Disease Control & Prevention (KCDC).
This study found the location of the coronavirus gene and RNA variations, to identify the transcriptome composition and the proliferation principles of the virus. In May, Theragen Bio traced the Seoul Itaewon cluster infections by sequencing the genomic materials and RNA transcriptomes and found that this SARS-CoV-2 variation originated in the U.S.
Theragen Bio, formerly the genome division of Theragen Etex (Kosdaq:066700), was spun off in March, 2020 to actively pursue customized pharmaceutical & new drug development and other projects featuring genomic technology. For further iniformation, please visit www.theragenbio.com.
Contact: Hyun Kim
Theragen Bio Co., Ltd.
Tel: +82-31-888-9313
Email: ngssales@theragenetex.com
Website: www.theragenbio.com
Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com
Captiva Verde Announces Esmeralda Agreement with Mexican Health Care Workers Union for up to USD$142 Million per Year of Annual Product Sales
Coquitlam, British Columbia, Jul 28, 2020 – (ACN Newswire) – Captiva Verde Land Corp. (CSE: PWR) (OTC: CPIVF) (the "Company" or "Captiva Verde"), is pleased to announce that further to its news release of October 2, 2019, where Captiva Verde has executed a share exchange agreement to acquire Salud Esmeralda de Mexico SA de CV, ("Esmeralda") where Esmeralda holds a comprehensive pharmaceutical license to sell, market and distribute an entire suite of 300+ pharmaceutical, health, wellness and veterinarian products which include all narcotic, psychoactive and non-psychoactive drugs listed under Groups I, II & III in Mexico, Esmeralda has today executed an agreement with the Chairman of both the 380,000 member Health Care Workers Union in Mexico and the broader 1.2 Million member Union Federation, whereby Esmeralda can expressly distribute and sell medicinal health and wellness products to the Union Federation on a direct basis, with payment from the Union.
 |
The Amount outlined in the agreement is for up to 1.2 Million members per month at between MXN $160 to MXN $220 per month, (between MXN $2.3 Billion to MXN $3.2 Billion per year) or up to USD $142,000,000 per year of product sales. (based on 30 day MXN-USD of 22.3) Captiva Verde is 75% complete in constructing its brand new drug manufacturing facility in Mexico for preparation of manufacturing and sales to the Union Federation this coming November. Anticipated Gross Profit is 40%. The complete cost of the new building is USD $750,000.
The Share Exchange Agreement between Esmeralda and Captiva Verde calls for the exchange of 80 Million shares subject to a strict pooling Agreement. Jeff Ciachurski, the CEO of Captiva Verde will receive 22.4 Million of those shares in this agreement. The Share Exchange Agreement and its resolutions are currently waiting for the filing of a signature verification process from the Mexican Consulate in Vancouver. Covid19 had previously delayed this basic administrative function. Final approval is then subject to the Canadian Securities Exchange once the Mexican Consulate has verified the Canadian resolutions including the corporate documents of Captiva Verde.
The exact wording in the Share Exchange Agreement reads:
https://tinyurl.com/yxvsvmdj
Jeff Ciachurski, the CEO of Captiva Verde, states: "This is an extremely significant milestone in the history of the Company. Without question, this agreement transforms Captiva Verde as a player in the legal health and wellness business, as we execute this function to one unified buyer, avoiding middlemen, agents, dealers and brokers, offering Mexican Union Members significant cost savings that are not available in the wholesale or retail market."
On Behalf of the Board of Directors
"Jeff Ciachurski"
Jeffrey Ciachurski
Chief Executive Officer and Director
Cell: (949) 903-5906
www.captivaverdecorp.com
E-mail: westernwind@shaw.ca
Cautionary Note Regarding Forward Looking Information
This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/60586
Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com
Impact Biomedical initiates Quantum Research Program to solve the Patent Cliff
SINGAPORE, Jul 27, 2020 – (ACN Newswire) – SGX-listed Singapore eDevelopment Limited's (SeD; SGX:40V) wholly-owned subsidiary Impact Biomedical Inc. ("Impact"), announced today the initiation of Quantum, their research program designed to solve the impending pharmaceutical patent cliff threat.
Impact Biomedical's transition to the Quantum research program comes on the heels of the completion of the research and development stage of its existing biodefense intellectual portfolio, which is now moving to the licensing and commercialization phase. The portfolio, valued by independent experts at approximately US$1.39 billion as announced by the Group on 1 June 2020 includes: Linebacker, a universal therapeutic designed to shadow the Panacea Project, a US Defense Advanced Research Projects Agency (DARPA) program to provide novel, multi-target therapeutics for unmet physiological needs; 3F BioFragrance, designed for the Open Air Defense Initiative, a strategy to protect locations where large numbers of people gather or transit; and Equivir, an OTC medication designed as an antiviral treatment and prophylactic comprising polyphenols that are GRAS or Generally Recognized as Safe, meaning its safety and behaviour in humans is already well understood and therefore is designed to proceed directly to human trials.
The patent cliff is a severe threat to pharmaceutical companies. The patent cliff arises when patents for blockbuster drugs expire without being replaced with new drugs, pharmaceutical companies experience an abrupt decrease in revenue. This depletes financial resources needed for the development of new therapeutics, which in turn reduces overall pharmaceutical innovation globally including crucial research into new methods to prevent and treat illnesses. The global pharmaceutical market research firm EvaluatePharma estimates that the patent cliff puts approximately US$198 billion in revenue at risk between 2019 and 2024[1]. Typical drug development uses schemes that have become less and less tenable. For example, drugs based on molecules found in cannabis are largely unpatentable due to the vast body of published research on new molecules derived from cannabis. Most existing techniques have already been contemplated. Without the patentability of the foregoing, the resources needed to develop a new drug based on cannabis cannot be secured.
Impact, through their strategic partner Global Research and Discovery Group Sciences ("GRDG"), has created a solution called Quantum, a new frontier in pharmaceutical development. Quantum is a new class of medicinal chemistry that uses advanced methods to boost efficacy and persistence of natural compounds and existing drugs while maintaining the safety profile of the original molecules. Instead of modifying functional groups, as is typically done presently in drug discovery, this new technique alters the behavior of molecules at the sub-molecular level. GRDG estimates that 65% of the World Health Organization Essential Medicines List can be improved and re-patented using Quantum. This approach can be used to enhance and patent natural compounds which includes many substances used in traditional medicines around the world.
This research follows the success of GRDG's recently completed exploratory program to address biomedical threats including the current COVID-19 pandemic which produced the 3F Antimicrobial BioFragrance, the universal therapeutic Linebacker, and the antiviral OTC medication Equivir, which is moving to human clinical trials. These inventions form the core of Impact's suite of next generation medical technology that was recently valued at approximately US$1.39 Billion by independent experts.
GRDG's Chief Scientific Advisor is Dr. Roscoe M. Moore, Jr., the former United States Assistant Surgeon General and former Epidemic Intelligence Service Officer at the U.S. Centers for Disease Control and Prevention. Dr. Moore said, "A new direction in drug discovery is sorely needed and Quantum has the potential to revive innovation and development of lifesaving pharmaceuticals."
GRDG's Chief Strategy Advisor is Lieutenant Colonel William H. Lyerly Jr., a retired U.S. Army Medical Service Corps Officer, as well as a retired Career Senior Executive / Scientific Professional (ST), with decorated civilian service as a senior official within the U.S. Department of Homeland Security, the U.S. Department of Health and Human Services, the U.S. Agency for International Development, and the U.S. Executive Office of the President (White House). Lieutenant Colonel Lyerly said, "Continued innovation in drug discovery is vital to combat new dangers to human health such as the current COVID-19 pandemic and beyond. Quantum can improve the drug development industry and enable scores of new solutions."
Impact Biomedical Chairman, Mr. Chan Heng Fai said, "Today, the difficulty in obtaining a pharmaceutical patent and retaining market exclusivity after it expires thwarts the momentum required by pharmaceutical companies to spur greater innovation. Backed by our newly established Quantum solution, we are proud to lead the field by bringing real and cutting-edge solutions to this immense global health challenge. In due time, we believe that Quantum will provide a practical solution for pharmaceutical companies to extend the patent life of their existing drug portfolio, thereby reducing abrupt declines in revenue following the expiration of patents. More importantly, they will be able to focus their resources on developing new, innovative drugs to treat and prevent illnesses for society at-large."
Daryl Thompson, Director of Scientific Initiatives and founder of GRDG, said, "The patent cliff represents a significant crisis in pharmaceutical innovation. The primary cause of the crisis is that most techniques for modifying natural molecules to pharmaceutical grade products are essentially 'played out.'
"Another way to explain this is that most of the methods to make drugs have already been published in scientific papers or rationalized in long expired patents. This means that these methods can render the development of new, novel compounds unpatentable. It is essential for a new drug in development qualify for patent protection due to the high costs of bringing a single compound to market. The medium cost of bringing a drug to market today is roughly US$985 million.
"Previous strategies for increasing the potency of a natural compound to pharmaceutically therapeutic levels employed the used of other molecular modification schemes. These techniques typically included standard practices such as altering functional groups, the addition or substitution of halogens and or the inclusion of lipid structures. The goal of these modifications would be to increase stimulation or inhibition of the molecule against its target site as well as increase bioavailability. Unfortunately, these effective techniques are being rendered moot due to lack of patentability due to prior disclosure.
"We have devised a method to break through this barrier and open a new path for drug development. We will be moving past macro-molecular techniques as mentioned above and will go deeper into the sub-atomic. Here we can look at molecular modification from the perspective of quantum physics. For instance, our previous work on the Linebacker program utilized halogenation to create electron rich portions in the molecule to increase its therapeutic potential. This technique, called sigma-hole generation or X-bonding, is well understood in the scientific community. However, once we disclose how we used this technique in a patent to create a new drug, it can never be patented again once the patents are expired.
"Quantum molecular modifications approach this problem from the perspective of manipulating the sub-atomic electron balance as a whole in consideration of the sum of both kinetic and potential energies within the molecular state. The exploitation of modification of this type by total energy configurations allows the use of quantum principles such as the Hamiltonian Operator as tools for understanding how to manipulate subatomic forces to increase a molecule's effectiveness as potential new life saving drug.
"This approach allows for a virtually endless array of methods that can lead to a new era in drug discovery possibilities. With our Biodefense mission complete, we will now move forward with the initialization of our Quantum Applications Research Platform. We expect to deliver the first 6 Quantum molecules to research institutes within three business quarters."
This new research will propel global drug discovery forward and foster increased innovation and ultimately better health worldwide.
There is currently no outlay of funds required for the initiation of Impact BioMedical's Quantum research program. Depending on the state of development of Quantum, SeD will fund its development through a variety of sources ranging from its internal source of funds and/or externally such as through funds generated from financial institutions as well as potential debt and/or equity fund raising.
Shareholders and potential investors of SeD should note that there is no certainty or assurance as at the date of this Press Release that Impact BioMedical's biodefense intellectual portfolio will be licensed or close to monetisation. Shareholders and potential investors of SeD are advised to read this Press Release and any further announcements made by SeD carefully. Shareholders and potential investors of SeD are advised to refrain from taking any action with respect to their securities in SeD which may be prejudicial to their interests, and to exercise caution when dealing in the securities of SeD. Shareholders and potential investors of SeD should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should take.
About Singapore eDevelopment Limited
Incorporated on 9 September 2009 and listed on the Singapore Exchange in July 2010, Singapore eDevelopment Limited is involved in (i) property development and investments primarily in the United States and Western Australia; (ii) information technology-related businesses; (iii) development, research, testing, manufacturing, licensing and distribution of biomedical products; and (iv) investment activities. For more information, please visit: www.SeD.com.sg or email contact@sed.com.sg.
About Impact BioMedical, Inc.
Impact BioMedical, Inc. ("Impact BioMedical") is a wholly-owned direct subsidiary of Global BioMedical Pte. Ltd., which in turn is a wholly-owned direct subsidiary of Singapore eDevelopment Limited, a company listed on the Singapore Exchange.
Impact BioMedical strives to leverage its scientific know-how and intellectual property rights to provide solutions that have been plaguing the biomedical field for decades. By tapping into the scientific expertise of GRDG Sciences, LLC. and Australian Exchange-listed Holista CollTech Limited, Impact BioMedical pledges to undertake a concerted effort in the R&D, drug discovery and development for the prevention, inhibition, and treatment of neurological, oncological and immuno related diseases.
About GRDG Sciences, LLC.
GRDG Sciences, LLC is an advanced research team formed in Florida by natural products discovery drug research scientist, Daryl Thompson. For more information, please visit: http://www.globalrdg.com.
[1] EvaluatePharma(R) World Preview 2019, Outlook to 2024 Report, 12th Edition, June 2019 https://tinyurl.com/y3lbhutm
Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com
Epazz DeskFlex Desk and Room Scheduling System Automates Desk Sanitation as Preventive Measure to Combat COVID-19 Infection in the Workplace
CHICAGO, IL, Jul 27, 2020 – (ACN Newswire) – via NEWMEDIAWIRE – Epazz, Inc. (OTC: EPAZ), a cloud-computing software company announced today that the DeskFlex desk and room scheduling system reconfigures its systems to include an automatic desk sanitation feature to prevent the onset or spread of the infection known as COVID-19 in workspaces.
DeskFlex's automatic scheduling desk sanitation is a program system configuration that allows the sanitation team to disinfect and clean desks, meeting rooms, workstations, conference rooms, and office equipment in between reservations. DeskFlex's room scheduling system activates desk sanitation after the ending of a reservation. It provides a 30-minute time gap to allow the cleaning crew to wipe, spray on, and sanitize the desks and frequently used items such as telephones.
DeskFlex's room booking system aspires to keep business establishments, schools, universities, organizations, and enterprises free from the COVID-19 infection. With the automation of desk sanitation in between reservations. The chances of spreading viral or bacterial particles in the workspace will lessen between each user.
DeskFlex's desk booking software has been in business since 1997 and is an exceptional desk hoteling and intelligent conference room booking software that is extremely useful in many industries including Health, Education, Business, Government, and Enterprise. Epazz acquired DeskFlex in 2008 and has been making major updates to the office hoteling system.
DeskFlex's room scheduling software upholds its mission in improving the lives of our customers' employees by providing accessible, user-friendly, reliable, and performance-driven desk hoteling and total office management software tools especially in challenging times like the current COVID-19 pandemic.
DeskFlex's room reservation online works hard to accommodate the surge of product requests coming from small and large organizations here and abroad. As the world returns to its office spaces, more and more organizations recognize the need for intelligent room booking software solutions that can help in preventing COVID-19 contamination in the workplace.
According to Shaun Passley, Ph.D., CEO of Epazz, Inc., "We are pleased to announce that DeskFlex's room booking software is now more adept in preventing COVID-19 infections from happening in the workplace by automating the cleaning of desks and rooms. Our team is working hard to improve our room scheduling system that includes preventive measures in combatting epidemics and maintaining a safe environment in the office."
About DeskFlex.com
DeskFlex is a desk booking solution and room reservation software for conference rooms, workspaces, car parking spaces, and equipment which helps office managers accommodate the occasional needs of mobile workers while reducing rent and facility costs. DeskFlex lets employees reserve a space in advance or claim desks right away. It adjusts the telephone switch (PBX), so calls ring at the "desk du jour." DeskFlex includes check-in, point-and-click floor maps, a web browser, a local kiosk, Outlook integration, and conference room scheduling.
About Epazz, Inc. (www.epazz.com)
Epazz, Inc., is a leading cloud-based software company that specializes in providing customized cloud applications to the corporate world, higher-education institutions, and the public sector. Epazz BoxesOS(TM) v3.0 is a complete web-based software package for small- to midsize businesses, Fortune 500 enterprises, government agencies, and higher education institutions. BoxesOS provides many of the web-based applications organizations would otherwise need to purchase separately. Epazz's other products are K9Sky.com kennel software and the Provitrac applicant tracking system.
SAFE HARBOR
This is the "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: certain statements contained in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by the use of forward-looking words such as "may," "expect," "intend," "estimate," "anticipate," "believe," and "continue" (or the negation thereof) or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from future results or those implied by such forward-looking statements. Investors are cautioned that no forward-looking statement is a guarantee of future performance and that actual results may differ materially from those contemplated by such forward-looking statements. Epazz, Inc. assumes no obligation and has no intention of updating these forward-looking statements. It has no obligation to update or correct information prepared by third parties that are not paid for by Epazz, Inc. Investors are encouraged to review Epazz, Inc.'s public filings on SEC.gov and otcmarkets.com, including its unaudited and audited financial statements and its OTC market filings, which contain general business information about the company's operations, results of operations, and risks associated with the company and its operations.
CONTACT: For more information, please contact
Investor Relations
investors@epazz.net
(312) 955-8161
www.epazz.com
Copyright 2020 ACN Newswire. All rights reserved. http://www.acnnewswire.com
theacnnewswire.news.blog 